deltatrials
Completed PHASE3 NCT00001038

A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients

A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients With Advanced HIV Infection (< 100 CD4+ Lymphocytes)

Sponsor: Glaxo Wellcome

Conditions Cytomegalovirus Infections HIV Infections
Interventions Acyclovir Valacyclovir hydrochloride
Updated 6 times since 2017 Last updated: Feb 28, 2011 Primary completion: May 31, 1996

This PHASE3 trial investigates Cytomegalovirus Infections and HIV Infections and is currently completed. Glaxo Wellcome leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Glaxo Wellcome
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States, Berlin, Germany, Bern, Switzerland, Birmingham, United States, Boston, United States, Calgary, Canada, Chapel Hill, United States, Chicago, United States, Columbus, United States, Denver, United States and 20 more location s